Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.32 |
| ▸ | HTR1D | P28221 | 2/20 | 0.31 |
| ▸ | HTR1B | P28222 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8598298 | 1.00 | GNAI3 (0.37) | GNAI3GNAO1GNAI1ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL2965976 | 0.98 | GNAI3 (0.40) | GNAI3GNAO1GNAI1ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL2965979 | 0.98 | GNAI3 (0.40) | GNAI3GNAO1GNAI1ADRB2ADRB1 | |
| SCHEMBL17730281 | 0.94 | EPHX2 (0.41) | GNAI3GNAO1GNAI1EPHX2SPHK1 | |
| SCHEMBL17730279 | 0.94 | EPHX2 (0.41) | GNAI3GNAO1GNAI1EPHX2SPHK1 | |
| SCHEMBL19554545 | 0.92 | GBA1 (0.43) | GNAI3GNAO1GNAI1EPHX2SPHK1 | |
| Hydrochloric Acid SCHEMBL22574872 | 0.92 | GBA1 (0.43) | GNAI3GNAO1GNAI1EPHX2SPHK1 | |
| Hydrochloric Acid SCHEMBL22574871 | 0.92 | GBA1 (0.43) | GNAI3GNAO1GNAI1EPHX2SPHK1 | |
| SCHEMBL19554547 | 0.92 | GBA1 (0.43) | GNAI3GNAO1GNAI1EPHX2SPHK1 | |
| SCHEMBL5986706 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-12-07 | — | — | US | disclosed |
| US-11124516-B2 | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | BIAL-BioTech Investments, Inc. (PT) | 2021-09-21 | — | — | US | disclosed |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-17 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-10934298-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | BIAL—BioTech Investments, Inc. (PT) | 2021-03-02 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
| EP-3215509-B1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20200030331-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2020-01-30 | — | — | US | disclosed |
| US-20190330213-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-10-31 | — | — | US | disclosed |
| US-20190315751-A1 | PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-10-17 | — | — | US | disclosed |
| WO-2019151269-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2019-08-08 | — | — | WO | disclosed |
| CN-107573249-B | A kind of preparation method of trans- 4- alkoxy cyclohexylamine | 上海馨远医药科技有限公司 | 2018-12-25 | — | — | CN | disclosed |
| US-20180185368-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-07-05 | — | — | US | disclosed |
| CN-107573249-A | A kind of preparation method of trans 4 alkoxy cyclohexylamine | 上海馨远医药科技有限公司 | 2018-01-12 | — | — | CN | disclosed |
| US-9840510-B1 | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315751-A1 | PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, GAA, SNCA | GNAI3 1052/4885GNAO1 72/4885GNAI1 420/4885 |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | GNAI3 259/4885GNAO1 51/4885GNAI1 127/4885 |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | GNAI3 1217/4885GNAO1 84/4885GNAI1 520/4885 |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, PARK7, GAA | GNAI3 311/4885GNAO1 53/4885GNAI1 146/4885 |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | GNAI3 1217/4885GNAO1 84/4885GNAI1 520/4885 |
| US-11124516-B2 | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | PARK7, GAA, SNCA | GNAI3 1052/4885GNAO1 72/4885GNAI1 420/4885 |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | GNAI3 467/4885GNAO1 49/4885GNAI1 252/4885 |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | GNAI3 195/4885GNAO1 126/4885GNAI1 148/4885 |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | GNAI3 467/4885GNAO1 49/4885GNAI1 252/4885 |
| US-10934298-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, GAA, PARK7 | GNAI3 203/4885GNAO1 54/4885GNAI1 96/4885 |
| US-20200030331-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | GNAI3 1217/4885GNAO1 84/4885GNAI1 520/4885 |
| US-20180185368-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | GNAI3 1217/4885GNAO1 84/4885GNAI1 520/4885 |
| US-20190330213-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | GNAI3 467/4885GNAO1 49/4885GNAI1 252/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | GNAI3 201/4885GNAO1 130/4885GNAI1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.